立方制药：部分董监高及股东拟减持股份

Group 1 - The company, Lifan Pharmaceutical (stock code 003020), announced that several key personnel and shareholders plan to reduce their holdings in the company [1] - Board member Wang Qing intends to reduce his holdings by no more than 321,200 shares, accounting for 0.17% of the company's total share capital [1] - Supervisor Wang Qin plans to reduce his holdings by no more than 143,400 shares, representing 0.07% of the total share capital [1] - Senior management member Dai Tianhe aims to reduce his holdings by no more than 142,900 shares, also 0.07% of the total share capital [1] - Senior management member Zheng Yong plans to reduce his holdings by no more than 104,100 shares, which is 0.05% of the total share capital [1] - Shareholder Gao Meihua intends to reduce his holdings by no more than 300,000 shares, accounting for 0.16% of the total share capital [1] Group 2 - The reduction period for these shareholdings is set from June 30, 2025, to September 29, 2025, and from June 12, 2025, to September 11, 2025 [1] - The method of reduction will be through centralized bidding or block trading [1]